Compass Therapeutics Inc [NASDAQ: CMPX] gained 30.07% on the last trading session, reaching $1.86 price per share at the time.
If compared to the average trading volume of 477.29K shares, CMPX reached a trading volume of 24153326 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Compass Therapeutics Inc [CMPX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CMPX shares is $11.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CMPX stock is a recommendation set at 1.38. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
D. Boral Capital have made an estimate for Compass Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 23, 2024. While these analysts kept the previous recommendation, Leerink Partners dropped their target price from $5 to $4. The new note on the price target was released on November 15, 2024, representing the official price target for Compass Therapeutics Inc stock. Previously, the target price had yet another raise to $5, while Ladenburg Thalmann analysts kept a Buy rating on CMPX stock.
The Average True Range (ATR) for Compass Therapeutics Inc is set at 0.21, with the Price to Sales ratio for CMPX stock in the period of the last 12 months amounting to 301.08. The Price to Book ratio for the last quarter was 1.85, with the Price to Cash per share for the same quarter was set at 0.98.
Trading performance analysis for CMPX stock
Compass Therapeutics Inc [CMPX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.28. With this latest performance, CMPX shares gained by 12.05% in over the last four-week period, additionally plugging by 95.36% over the last 6 months – not to mention a rise of 2.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CMPX stock in for the last two-week period is set at 63.15, with the RSI for the last a single of trading hit 68.42, and the three-weeks RSI is set at 59.54 for Compass Therapeutics Inc [CMPX]. The present Moving Average for the last 50 days of trading for this stock 1.5780, while it was recorded at 1.5660 for the last single week of trading, and 1.4697 for the last 200 days.
Compass Therapeutics Inc [CMPX]: A deeper dive into fundamental analysis
Compass Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 31.84 and a Current Ratio set at 31.84.
An analysis of Institutional ownership at Compass Therapeutics Inc [CMPX]
There are presently around $69.16%, or 79.09%% of CMPX stock, in the hands of institutional investors. The top three institutional holders of CMPX stocks are: ORBIMED ADVISORS LLC with ownership of 22.36 million shares, which is approximately 16.3701%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 11.13 million shares of the stock with an approximate value of $$11.13 million in CMPX stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$7.69 million in CMPX stock with ownership which is approximately 5.6304%.
